Save Product
Product Details
Synonyms
BTLA, CD272
Source
Biotinylated Human BTLA (31-150), Fc,Avitag (BTA-H82F3) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Ser 150 (Accession # AAP44003.1).
Predicted N-terminus: Lys 31
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human BTLA (31-150), Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Human BTLA (31-150), Fc,Avitag (Cat. No. BTA-H82F3) is more than 85% and the molecular weight of this protein is around 100-140 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BTLA (31-150), Fc,Avitag (Cat. No. BTA-H82F3) with a linear range of 0.02-0.625 μg/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
- Product
Why are different expression ranges (31–134 and 31–150) used for human BTLA proteins?
The different lengths of human BTLA proteins correspond to different isoforms. The aa31–134 sequence represents isoform 2, while aa31–150 corresponds to isoform 1. ACRO provides BTLA proteins of varying lengths to meet diverse customer requirements.
Background
Recent Advances
Drug Development Progress- English Name：
B- and T-lymphocyte attenuator
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
6 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
